Entrada Therapeutics earnings were $55.0M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest TRDA earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$14.0M, down 125.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, TRDA reported annual earnings of -$6.7M, with -92.9% growth.
TRDA past earnings growth
How has TRDA's earnings growth performed historically?
Entrada Therapeutics Earnings Reports & History FAQ
What were Entrada Therapeutics's earnings last quarter?
Entrada Therapeutics (NASDAQ: TRDA) reported Q3 2024 earnings per share (EPS) of -$0.35, up 132.71% year over year. Total TRDA earnings for the quarter were -$14.03 million. In the same quarter last year, Entrada Therapeutics's earnings per share (EPS) was $1.07.
Is Entrada Therapeutics profitable or losing money?
As of the last Entrada Therapeutics earnings report, Entrada Therapeutics is currently profitable. Entrada Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was $54.95 million, a 352.42% decrease year over year.
What was TRDA's earnings growth in the past year?
As of Entrada Therapeutics's earnings date in Q1 2025, Entrada Therapeutics's earnings has grown year over year. TRDA earnings in the past year totalled $54.95 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.